<DOC>
	<DOCNO>NCT01390012</DOCNO>
	<brief_summary>The purpose study assess bioequivalence dexamethasone administer orally versus intravenously patient admit hospital pneumonia .</brief_summary>
	<brief_title>Oral Versus Intravenous Dexamethasone</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Aged 18 year old Presenting emergency room suspect pneumonia ( confirm within 24 hour admission ) Pneumonia define new progressive infiltrate chest Xray plus least two follow criterion : cough , sputum production , temperature &gt; 38°C &lt; 35°C , auscultatory finding consistent pneumonia , leucocytosis leucopenia ( &gt; 10 g/l , &lt; 4 g/l &gt; 10 % rod leucocyte differentiation ) , Creactive protein &gt; 3 time upper normal limit Corticosteroid naive time presentation Patients need corticosteroid treatment study medication Failure obtain write consent participate Patients use medication drug interact dexamethasone ( i.e . phenytoin , barbiturate , rifampicin , erythromycin , clarithromycin , aprepitant , colchicine , everolimus , itraconazole , ketoconazole , pazopanib , tipranavir , vinorelbine ) Moribund patient ( define expect die within 24 hour ) Patients proven suspect allergy dexamethasone Patients capable take tablet orally</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>